Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials

Antonio Galvano, Diego Molteni, Davide Molteni, Alberto Donzelli, Maria Font, Alessandro Battaggia

Risultato della ricerca: Articlepeer review

21 Citazioni (Scopus)


Background: Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes. Methods and Findings: We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same dosage, with a follow-up at least 24 weeks and one or more of these outcomes: all-cause mortality, cardiovascular (CV) mortality, stroke, myocardial infarction (MI), cancer, serious adverse events (SAEs); we assessed the risk of bias using the Cochrane checklist. We extracted the data for major clinical events as a dichotomous measure, with the patient the unit of analysis. Pooled analysis was done with random and fixed effect based models. Trials comparing Ezetimibe plus a lipid-lowering drug against the same lipidlowering drug representing the net effect of Ezetimibe, showed a nonsignificant tendency toward damage for cancer, MI, stroke and SAEs. Ezetimibe+simvastatin vs. simvastatin alone showed a stronger tendency towards a higher risk for all-cause death (2.52; 0.65-9.74), CV death (3.04; 0.48-19.21), non-CV death (3.03; 0.12-73.50), MI (1.91; 0.42-8.70), stroke (2.38; 0.46-12.35), cancer (RR 11.11; 0.62-198.29), and SAEs (1.45; 0.95-2.23). Limitations include small numbers of events and inadequate power of the pooling. Trials comparing Ezetimibe+simvastatin vs placebo showed non-significant effects: MI (0.81; 0.66-1.00 p = 0.051), all-cause death (1.02; 0.95-1.09), CV death (0.91; 0.80-1.04), non-CV death (108; 0.99-1.18), stroke (0.86; 0.72-1.04), cancer (1.18; 0.80-1.74), SAEs (1.01; 0.96-1.06). Conclusions: Ezetimibe±simvastatin had inconsistent effects on important outcomes. No firm conclusions are possible, but findings indicative of damage suggest much more selective use of Ezetimibe±simvastatin.
Lingua originaleEnglish
pagine (da-a)e0124587-
Numero di pagine24
RivistaPLoS One
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.1300.1300???
  • ???subjectarea.asjc.1100.1100???
  • ???subjectarea.asjc.1000???


Entra nei temi di ricerca di 'Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials'. Insieme formano una fingerprint unica.

Cita questo